Conference Coverage

PEXIVAS trial results will likely change ANCA-associated vasculitis therapy

Publish date: October 25, 2018

 

REPORTING FROM THE ACR ANNUAL MEETING

SOURCE: Merkel PA et al. Arthritis Rheumatol. 2018;70(Suppl 10):Abstract 2788.

Pages

Recommended Reading

Anti-RNPC3 antibody positive status linked to GI dysmotility in systemic sclerosis
MDedge Rheumatology
Long-term follow-up results of ongoing trials highlighted at ACR 2018
MDedge Rheumatology
Third ACR Plenary presentations set to make an impact in rheumatology
MDedge Rheumatology
Inflammatory arthritis a common rheumatic adverse event with ICIs
MDedge Rheumatology
Antimalarial-induced cardiomyopathy in lupus may be underrecognized
MDedge Rheumatology
PET/CT has good accuracy for diagnosing GCA
MDedge Rheumatology
Ablation plus transplant for severe scleroderma shows 11-year benefits
MDedge Rheumatology
Case review: Posttransplant lupus nephritis recurrence rates declining
MDedge Rheumatology
SLE low-disease definition receives prospective validation
MDedge Rheumatology
Drafts of new classification criteria presented for GCA, Takayasu’s arteritis
MDedge Rheumatology